These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37418548)

  • 1. Restoring tumor immunogenicity with dendritic cell reprogramming.
    Zimmermannova O; Ferreira AG; Ascic E; Velasco Santiago M; Kurochkin I; Hansen M; Met Ö; Caiado I; Shapiro IE; Michaux J; Humbert M; Soto-Cabrera D; Benonisson H; Silvério-Alves R; Gomez-Jimenez D; Bernardo C; Bauden M; Andersson R; Höglund M; Miharada K; Nakamura Y; Hugues S; Greiff L; Lindstedt M; Rosa FF; Pires CF; Bassani-Sternberg M; Svane IM; Pereira CF
    Sci Immunol; 2023 Jul; 8(85):eadd4817. PubMed ID: 37418548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprogramming Cancer Cells to Antigen-presenting Cells.
    Ferreira AG; Zimmermannova O; Kurochkin I; Ascic E; Åkerström F; Pereira CF
    Bio Protoc; 2023 Nov; 13(22):e4881. PubMed ID: 38023788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells.
    Rosa FF; Pires CF; Kurochkin I; Halitzki E; Zahan T; Arh N; Zimmermannová O; Ferreira AG; Li H; Karlsson S; Scheding S; Pereira CF
    Sci Immunol; 2022 Mar; 7(69):eabg5539. PubMed ID: 35245086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
    Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.
    Ferris ST; Ohara RA; Ou F; Wu R; Huang X; Kim S; Chen J; Liu TT; Schreiber RD; Murphy TL; Murphy KM
    Cancer Immunol Res; 2022 Aug; 10(8):920-931. PubMed ID: 35648641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
    Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Reprogramming of Mouse Embryonic Fibroblasts to Conventional Type 1 Dendritic Cells by Enforced Expression of Transcription Factors.
    Rosa FF; Pires CF; Zimmermannova O; Pereira CF
    Bio Protoc; 2020 May; 10(10):e3619. PubMed ID: 33659292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo dendritic cell reprogramming for cancer immunotherapy.
    Ascic E; Åkerström F; Sreekumar Nair M; Rosa A; Kurochkin I; Zimmermannova O; Catena X; Rotankova N; Veser C; Rudnik M; Ballocci T; Schärer T; Huang X; de Rosa Torres M; Renaud E; Velasco Santiago M; Met Ö; Askmyr D; Lindstedt M; Greiff L; Ligeon LA; Agarkova I; Svane IM; Pires CF; Rosa FF; Pereira CF
    Science; 2024 Oct; 386(6719):eadn9083. PubMed ID: 39236156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
    Montoya M; Collins SA; Chuntova P; Patel TS; Nejo T; Yamamichi A; Kasahara N; Okada H
    Neuro Oncol; 2024 Aug; ():. PubMed ID: 39115195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
    Montoya M; Collins SA; Chuntova P; Patel TS; Nejo T; Yamamichi A; Kasahara N; Okada H
    bioRxiv; 2024 Apr; ():. PubMed ID: 38617245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular cytotoxicity is a form of immunogenic cell death.
    Minute L; Teijeira A; Sanchez-Paulete AR; Ochoa MC; Alvarez M; Otano I; Etxeberrria I; Bolaños E; Azpilikueta A; Garasa S; Casares N; Perez Gracia JL; Rodriguez-Ruiz ME; Berraondo P; Melero I
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8
    Darling R; Senapati S; Christiansen J; Liu L; Ramer-Tait AE; Narasimhan B; Wannemuehler M
    Int J Nanomedicine; 2020; 15():6579-6592. PubMed ID: 32982219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
    Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
    Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
    Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
    Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
    Front Immunol; 2018; 9():822. PubMed ID: 29755461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.